FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction
The Pharma Data
JANUARY 20, 2021
FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction. mg, 5 mg, and 10 mg tablets is being jointly developed with Bayer AG. The Verquvo label contains a boxed warning that indicates that Verquvo should not be administered to pregnant females because it may cause fetal harm. KENILWORTH, N.J.–(BUSINESS
Let's personalize your content